Cyclerion Therapeutics, Inc.CYCNEarnings & Financial Report
Nasdaq
NextNov 12, 2026
CYCN Q3 2025 Key Financial Metrics
Revenue
$875.0K
Gross Profit
N/A
Operating Profit
$-1.0M
Net Profit
$-976.0K
Gross Margin
N/A
Operating Margin
-115.0%
Net Margin
-111.5%
YoY Growth
351.0%
EPS
$-0.30
Financial Flow
Cyclerion Therapeutics, Inc. Q3 2025 Financial Summary
Cyclerion Therapeutics, Inc. reported revenue of $875.0K for Q3 2025, with a net profit of $-976.0K (-111.5% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $875.0K |
|---|---|
| Net Profit | $-976.0K |
| Gross Margin | N/A |
| Operating Margin | -115.0% |
| Report Period | Q3 2025 |
Cyclerion Therapeutics, Inc. Annual Revenue by Year
Cyclerion Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $2.0M).
| Year | Annual Revenue |
|---|---|
| 2024 | $2.0M |
| 2023 | $0 |
| 2022 | $1.6M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $194000 | $1.8M | $81000 | $93000 | $875000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 351.0% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $13.4M | $11.4M | $10.1M | $8.9M | $9.6M | $9.8M | $9.4M | $10.4M |
| Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Equity | $11.3M | $9.9M | $8.8M | $8.2M | $8.8M | $8.8M | $8.6M | $9.5M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-1.5M | $-1.9M | $-1.1M | $-1.7M | $360000 | $-968000 | $-503000 | $-264000 |